Welcome to our dedicated page for Corvex news (Ticker: MOVE), a resource for investors and traders seeking the latest updates and insights on Corvex stock.
Movano Inc. (Nasdaq: MOVE), doing business as Movano Health, generates news at the intersection of wearable medical devices, health technology, and corporate transformation. Founded in 2018, the company develops devices such as the Evie and EvieMED rings, which are designed to bring medical-grade data into consumer and enterprise wearables. Its disclosures highlight capabilities that span physiological monitoring, women’s wellness, and proprietary RF-based sensing for cuffless blood pressure and noninvasive glucose monitoring.
News coverage of Movano frequently includes product and technology updates. The company has announced clinical study results for its wrist-worn cuffless blood pressure prototype, noting accuracy within standards recognized by the FDA for wearable, cuffless blood pressure devices and the ability to collect additional vital signs such as pulse rate, SpO2, respiration rate and ECG waveforms. It has also reported enhancements to the Evie Ring’s companion app, including new personalization and trend-tracking features, integration with Apple Health, expanded workout logging, and the introduction of EvieAI, a virtual wellness assistant built from medical journal data.
Movano’s news flow also reflects regulatory and listing developments. The company has issued multiple press releases regarding Nasdaq notifications related to bid price, periodic filing timeliness, and stockholders’ equity requirements, as well as its responses, such as engaging a new independent auditor, submitting compliance plans, and implementing a one-for-ten reverse stock split to support bid price compliance. Investors following MOVE news can track how these steps affect the company’s continued listing on the Nasdaq Capital Market.
A significant portion of recent headlines centers on strategic and transactional events. Movano’s board initiated a process to explore strategic alternatives, including a sale or merger, to maximize shareholder value. This process led to a definitive Agreement and Plan of Merger with Corvex, Inc., an AI cloud computing company specializing in GPU-accelerated infrastructure. Related announcements describe the planned all-stock combination, ownership structure expectations, concurrent financings, and the intention to rename Movano Inc. as Corvex, Inc. upon closing, with the combined company headquartered in Arlington, Virginia. Movano has also communicated that it may market for sale its current operating assets, including the EvieMED Ring and its mmWave RF technology, prior to completion of the merger.
By monitoring the MOVE news feed, readers can follow updates on Movano’s wearable health products, clinical and regulatory milestones, listing status, financing activities, and the progress of its proposed merger with Corvex. This stream of information helps investors and observers understand both the company’s health technology initiatives and its potential evolution into a public vehicle for AI infrastructure through the planned combination.
Movano Health (Nasdaq: MOVE) announced a proposed underwritten public offering of shares and warrants to purchase common stock. The offering will be conducted by the company, which aims to grant the underwriter a 30-day option for an additional 15% of shares. Proceeds will support general corporate purposes, including product development and commercialization. Newbridge Securities Corporation is the sole book-running manager for the offering. The final terms are subject to market conditions, and the offering will be registered with the SEC. The company cautions that actual results may vary due to inherent risks and uncertainties.
Summary not available.
Summary not available.
Movano Health (Nasdaq: MOVE) plans to file for FDA clearance for its new women-focused wearable, the Evie smart ring, which integrates medical-grade health data into a user-friendly mobile app. Designed to enhance women's health insights, Evie will provide metrics including heart rate, SpO2, and menstrual tracking, aiming to empower users to make informed health decisions without a subscription fee. Following a successful hypoxia trial confirming accuracy, Evie is set to debut at CES 2023, priced below $300 and available in 2023.
Movano Health (NASDAQ: MOVE) announced promising preliminary results from its pivotal hypoxia trial, demonstrating a 2% margin of error for blood oxygen saturation (SpO2) and a heart rate error of 2 BPM. Both metrics exceeded FDA standards, indicating high accuracy. The trial involved 11 subjects and followed an FDA-required protocol. Movano plans to file for FDA clearance in 2023. CEO John Mastrototaro emphasized the importance of developing wearable devices that empower consumers with reliable health data.
Movano Health has initiated a beta program for its smart ring, designed to track and analyze medical-grade data, in collaboration with Novant Health. Approximately 30 team members from Novant will assess the smart ring's functionality and wearability. The beta program, set to commence this month, aims to prepare Movano for its product launch targeted for the first half of 2023. The collaboration underscores a shared goal of making healthcare more accessible and could provide vital feedback for Movano's technology development in consumer health.
Movano Health (Nasdaq: MOVE) announced participation in several investor-focused events to discuss progress on its smart ring and an integrated circuit for blood pressure and glucose monitoring. Upcoming events include the Bernstein CGM Disruptors Conference on November 18, 2022, the BTIG Digital Health Forum on November 21, 2022, and the Benchmark Discovery Conference on December 1, 2022. These invite-only conferences aim to connect with clients and stakeholders. For more information, visit movanohealth.com.
Movano Inc. (NASDAQ:MOVE) reported Q3 2022 financial results, showing a net loss of $8.6 million, or $(0.26) per share, up from a loss of $5.2 million in Q3 2021. The company will begin beta testing its smart wearables with Stanford University and Novant Health, aiming for FDA approval in early 2023. Movano has $16.8 million in cash, a decrease from $33.6 million at the end of 2021. Additionally, it plans to initiate blood pressure and glucose studies by year-end 2022. The conference call discussing these results is scheduled for today at 2:00 p.m. PST.
Movano Inc. (NASDAQ: MOVE) will report its third quarter 2022 financial results on November 14, 2022. A conference call and live audio webcast will take place at 2:00 p.m. PDT to discuss these results and provide business updates. The company's focus is on developing healthcare solutions that integrate medical-grade data into consumer devices, aiming to help users proactively manage their health. Movano emphasizes its commitment to innovation within the medtech industry.
Movano Inc. (NASDAQ:MOVE) announced its Q2 2022 financial results, reporting a net loss of $6.9 million, compared to $4.7 million in Q2 2021. The company has initiated beta testing programs for its Movano Ring with partners like Stanford University, targeting a direct-to-consumer launch in H1 2023. Recent studies demonstrated the Ring's accuracy in measuring blood oxygen and heart rate, crucial for FDA submission. Movano also plans further clinical studies on blood pressure and glucose monitoring using its patented system-on-a-chip technology. The company held $21.3 million in cash as of June 30, 2022.